etodolac has been researched along with sdx 308 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aleskog, A; Chao, Q; Elliott, G; Larsson, R; Leoni, L; Lindhagen, E; Nissle, S | 1 |
| Anderson, KC; Carrasco, DR; Chauhan, D; Hideshima, T; Ikeda, H; Kiziltepe, T; Neri, P; Ocio, EM; Okawa, Y; Podar, K; Raje, N; Richardson, PG; Sukhdeo, K; Vallet, S; Yasui, H | 1 |
| Aleskog, A; Elliott, G; Larsson, R; Leoni, L; Lindhagen, E; Nygren, P; Rickardson, L | 1 |
| Elliott, G; Lentzsch, S; Roodman, GD | 1 |
| Feng, R; Lentzsch, S | 1 |
| Robak, P; Robak, T; Smolewski, P | 1 |
3 review(s) available for etodolac and sdx 308
| Article | Year |
|---|---|
SDX-308 and SDX-101, non-steroidal anti-inflammatory drugs, as therapeutic candidates for treating hematologic malignancies including myeloma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Etodolac; Hematologic Neoplasms; Heterocyclic Compounds, 3-Ring; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; NF-kappa B; Osteoclasts; Stereoisomerism | 2007 |
Treatment of multiple myeloma with SDX-308.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Bone Diseases; Drug Therapy; Etodolac; Heterocyclic Compounds, 3-Ring; Humans; Multiple Myeloma; Osteoclasts; Tumor Necrosis Factor-alpha | 2007 |
The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Etodolac; Hematologic Neoplasms; Heterocyclic Compounds, 3-Ring; Humans | 2008 |
3 other study(ies) available for etodolac and sdx 308
| Article | Year |
|---|---|
R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chlorambucil; Doxorubicin; Drug Synergism; Etodolac; Female; Heterocyclic Compounds, 3-Ring; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Vincristine | 2007 |
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etodolac; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Signal Transduction; TCF Transcription Factors | 2007 |
Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Etodolac; Female; Heterocyclic Compounds, 3-Ring; Humans | 2007 |